Stifel holds TransMedics Group stock at USD 65.00 amid competition

Published on 10/20/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 189.95 million, up 21.00 percent. TMDX stock costs EUR 63.44 on October 20, 2026; market value is USD 2.5 billion.

Targets, growth and trading

Stifel kept a Hold rating and a USD 65.00 target on October 15, 2026.
Second-quarter revenue reached USD 189.95 million, up 21.00 percent year over year.
TransMedics Group stock was trading at EUR 63.44 at 2:34 p.m. CEST at Lang & Schwarz on October 20, 2026.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group (ISIN US89377M1099) was trading at EUR 63.44 at Lang & Schwarz on October 20, 2026, at 2:34 p.m. CEST. Investing.com reported on October 15, 2026, that Stifel kept a Hold rating and a USD 65.00 price target because of longer-term competition concerns.

Stifel flags competition risk

Stifel estimated third-quarter 2026 revenue at USD 185 million to USD 190 million, above the USD 178 million Street estimate, according to Investing.com. The same report said Stifel viewed competition as a possible multi-year overhang and modeled 2027 earnings per share of USD 1.75.

What does competition mean for targets?

The USD 65.00 target sits below several recent broker views. Markets Insider reported on October 13, 2026, that Canaccord lowered its target from USD 95.00 to USD 94.00 while keeping a Buy rating. Barclays had initiated coverage on October 6, 2026, with an Overweight rating and a USD 120.00 target, according to Markets Insider.

Three dates show the progression

On August 4, 2026, TransMedics reported second-quarter revenue of USD 189.9 million, up 21.00 percent from the prior-year quarter, through its investor relations page. On September 10, 2026, the company appointed Fernando Araujo as chief financial officer and reiterated 2026 revenue guidance of USD 737 million to USD 757 million, according to TransMedics. Stifel's October 15, 2026, rating and USD 65.00 target were the latest dated event.

Next reporting dates

MarketBeat lists October 28, 2026, for the third-quarter conference call and estimates November 4, 2026, for the earnings announcement.

Growth meets a lower margin

The second-quarter report showed the tension behind the debate: revenue increased to USD 189.948 million, but operating margin fell to 12.5 percent from 23.2 percent a year earlier. Adjusted diluted earnings per share were USD 0.44, while GAAP diluted earnings per share were USD 0.41. The company also raised the low end of its 2026 revenue guidance to USD 737 million, excluding PAD Aviation revenue.

Trading status in Germany

TransMedics Group is listed on Nasdaq under ticker TMDX. Its market capitalization was USD 2.5 billion as of October 19, 2026, while its 52-week range was USD 60.10 to USD 156.00.

The stock was trading at EUR 63.44 at Lang & Schwarz on October 20, 2026, at 2:34 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of TransMedics Group stock.